Dr. McKay Discusses Advances in the Treatment of Metastatic RCC

Video

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma.

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma (RCC).

One of the most influential studies over the past few years has been the CheckMate-025 study in patients with metastatic clear cell RCC, says McKay. This was the first time that a second-line treatment was shown to improve overall survival in this population.

Studies with cabozantinib (Cabometyx), ipilimumab (Yervoy) plus nivolumab (Opdivo), and sunitinib (Sutent) have also enriched the treatment landscape of metastatic RCC, McKay adds.

Related Videos
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD